Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
NewAmsterdam Pharma Company N.V.
NAMS
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.1B
$34.54
▼ -1.80%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$18.70 - $42.21
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 85.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel selective CETP inhibitor with dual lipid-modifying mechanism
- First-mover advantage in next-generation CETP inhibition
- Strong clinical validation demonstrating LDL reduction and HDL elevation
- Experienced management team with deep biopharmaceutical expertise
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
Advancement of obicetrapib through clinical development pipeline
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+6.6% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NAMS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 7, 2026
Reported EPS of -$0.40 vs -$0.46 consensus (+13.0% surprise). Revenue of $3.0M vs $1.7M expected (+72.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+13.0%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
—
—
+740%
-99%
-100%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$2.3M
$29.1M
$12.8M
$3.0M
$19.1M
$348.0K
$32.0K
$3.0M
Margins · last 8Q
Gross
83.6%
Operating
—
Profit
-1593.5%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jun 30, 2026
vs Industry
How NAMS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related
Peers & themes
Peers
No peer data available.
Themes
No themes assigned.